Trial Profile

A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JS-207 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai Junshi Biosciences

Most Recent Events

28 Feb 2025 Planned End Date changed from 26 Sep 2025 to 30 Jun 2026.
28 Feb 2025 Planned primary completion date changed from 30 Nov 2024 to 31 Dec 2025.
17 Jul 2024 Planned number of patients changed from 162 to 192.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com